Nipp Ryan D, Rao Arati V
Department of Medicine, Duke University Medical Center, Durham, North Carolina.
J Gerontol A Biol Sci Med Sci. 2015 Jun;70(6):714-21. doi: 10.1093/gerona/glt039. Epub 2013 Jun 19.
Acute myeloid leukemia (AML) is an aggressive disease that predominantly affects elderly patients. Cytokines and chemokines are major players in the pathogenesis of AML. They regulate the disease course and play a deleterious role in the progression of AML. The geriatric population is particularly vulnerable to these mediators as these cytokines and chemokines are also implicated in the development of frailty, fatigue, and declining cognitive function. It is the combination of these adverse effects of cytokines and chemokines that affect performance status and, in turn, the poor prognosis in this age group. Cytokines and chemokines are emerging as therapeutic targets in AML. Future endeavors to treat AML will likely involve cytokines and chemokines as attempts are made to disrupt the bone marrow environment. By modulating the bone marrow stroma, the goal is to create an environment less favorable to AML cells and more favorable to the effects of chemotherapy against AML.
急性髓系白血病（AML）是一种侵袭性疾病，主要影响老年患者。细胞因子和趋化因子是AML发病机制中的主要参与者。它们调节疾病进程，并在AML进展中起有害作用。老年人群对这些介质特别敏感，因为这些细胞因子和趋化因子也与虚弱、疲劳和认知功能下降的发生有关。正是细胞因子和趋化因子的这些不良反应共同影响了身体机能状态，进而导致该年龄组预后不良。细胞因子和趋化因子正成为AML的治疗靶点。未来治疗AML的努力可能会涉及细胞因子和趋化因子，因为人们试图破坏骨髓环境。通过调节骨髓基质，目标是创造一个对AML细胞不利、对化疗治疗AML的效果更有利的环境。
